ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

MOR MorphoSys AG

17,87
-0,31 (-1,71%)
25 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
MorphoSys AG MOR NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
-0,31 -1,71% 17,87 22:30:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
18,06 17,80 18,20 17,87 18,18
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
20/6/202408:47BWMorphoSys and Novartis Sign Delisting Agreement and Intend..
10/6/202417:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/6/202422:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/6/202416:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/6/202422:06EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
04/6/202416:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/5/202416:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/5/202416:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/5/202416:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/5/202416:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/5/202420:19EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
23/5/202416:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/5/202415:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/5/202416:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/5/202416:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/5/202422:43EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
16/5/202416:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/5/202416:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/5/202416:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/4/202422:01BWMorphoSys AG Reports First Quarter 2024 Financial Results
11/4/202414:39BWMorphoSys’ Management Board and Supervisory Board Recommend..
13/3/202421:02BWMorphoSys AG Reports Fourth Quarter and Full Year 2023..
06/2/202412:14IHMARKETNEWSBoeing Faces Strike Threat, Palantir Up 18% After Recording..
11/12/202301:31BWMorphoSys’ Pelabresib Improves All Four Hallmarks of..
20/11/202323:19DJNMorphoSys Trial for Blood-Cancer Treatment Reaches Primary..
20/11/202322:30BWMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis..
15/11/202322:01BWMorphoSys AG Reports First Nine Months and Third Quarter..
09/8/202322:01BWMorphoSys AG Reports Second Quarter and First Half 2023..